Weak cold and flu season hits RB's OTC sales

6 May 2019 - Deborah Wilkes

Premium

Worldwide OTC sales at RB dropped by 9% on a like-for-like basis to GBP470 million (USD603 million) in the first quarter of 2019. The company blamed an "unusually weak cold and flu season across the US and several European markets" plus "associated retailer destocking".

Click tags below for more information on topics:

RB

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: